BLIJVEN, Based on five major technology platforms, We have developed several blockbuster peptide drugs such as semaglutide and liraglutide. At the same time, it has formed a complete product layout in medical beauty peptide medicines, antiviral peptide drugs and vaccines, medical beauty protein raw materials and ophthalmology.

In terms of medical beauty raw materials, we have cooperated with a doctoral team from Shandong University of Technology to establish an exosome production and separation and purification workshop, and started to develop products using exosomes as raw materials. Animal experiments on related products are underway.

In term of generic drugs and new drug projects, including the development of targeted peptide (PDC) projects, benchmarking against ADC drugs, treating cancer, using AI technology to assist in new drug development, and transferring technology to large domestic and foreign pharmaceutical companies.

In 2024, we obtained the Shenzhen Specialized and New Enterprise Certification and became one of the "Little Giant" enterprises.